Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
Authorization Represents Significant Advancement in the Global Response to Ebola
Merck Remains Committed to Working with International Health Partners in Ebola Outbreak Response
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has granted a conditional marketing authorization to ERVEBO for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of ERVEBO should be in accordance with official recommendations. The approval is based on data submitted to the European Medicines Agency for accelerated assessment in March 2019.
Media:
Pamela Eisele
267-305-3558
Skip Irvine
267-305-0338
Investors:
Peter Dannenbaum
908-740-1037
Michael DeCarbo
908-740-1807
